Cyteir Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 46
- Market Cap
- -
- Website
- http://www.cyteir.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Multiple MyelomaSoft Tissue SarcomaHead and Neck CancerNon-hodgkin LymphomaOvarian CancerDLBCLMalignancyMantle Cell LymphomaCLLSquamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: CYT-0851 in combination with gemcitabineDrug: CYT-0851 in combination with capecitabineDrug: CYT-0851 in combination with rituximab and bendamustine
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Cyteir Therapeutics, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03997968
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Stanford Comprehensive Cancer Center, Stanford, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
News
No news found